Demo Data from EDBT 2026 / reviewers in the wild / expert
Yueqian Deng
dblp:425/2884
· DBLP profile ↗
1ranked-venue papers
0as first author
1since 2021 · last 2025
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 3 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › cancer genomics
circulating tumor DNA analysis |
0.9 | 1 | 2025 | Marker selection strategies for circulating tumor DNA guided by phylogenetic inference · Bioinform. 2025 |
Bioinformatics and computational biology › cancer genomics › tumor evolution
clonal evolution |
0.9 | 1 | 2025 | Marker selection strategies for circulating tumor DNA guided by phylogenetic inference · Bioinform. 2025 |
Bioinformatics and computational biology › gene expression analysis › gene expression classification
marker gene selection |
0.9 | 1 | 2025 | Marker selection strategies for circulating tumor DNA guided by phylogenetic inference · Bioinform. 2025 |
Methods — techniques the papers use, named apart from their topics
probabilistic modeling · 0.9phylogenetic inference · 0.9optimization · 0.9bootstrap sampling · 0.9
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2025 | Marker selection strategies for circulating tumor DNA guided by phylogenetic inferenceabstractMOTIVATION: Blood-based profiling of tumor DNA ("liquid biopsy") offers great prospects for non-invasive early cancer diagnosis and clinical guidance, but requires further computational advances to become a robust quantitative assay of tumor clonal evolution. We propose new methods to better characterize tumor clonal dynamics from circulating tumor DNA (ctDNA), through application to two specific tasks: (i) applying longitudinal ctDNA data to refine phylogeny models of clonal evolution, and (ii) quantifying changes in clonal frequencies that may be indicative of treatment response or tumor progression. We pose these through a probabilistic framework for optimally identifying markers and using them to characterize clonal evolution. RESULTS: We first estimate a density over clonal tree models using bootstrap samples over pre-treatment tissue-based sequence data. We then refine these models over successive longitudinal samples. We use the resulting framework for modeling and refining tree densities to pose a set of optimization problems for selecting ctDNA markers to maximize measures of utility for reducing uncertainty in phylogeny models and quantifying clonal frequencies given the models. We tested our methods on synthetic data and showed them to be effective at refining tree densities and inferring clonal frequencies. Application to real tumor data further demonstrated the methods' effectiveness in refining a lineage model and assessing its clonal frequencies. The work shows the power of computational methods to improve marker selection, clonal lineage reconstruction, and clonal dynamics profiling for more precise and quantitative assays of somatic evolution and tumor progression. AVAILABILITY AND IMPLEMENTATION: https://github.com/CMUSchwartzLab/Mase-phi.git. (DOI: 10.5281/zenodo.14776163). Xuecong Fu, Zhicheng Luo, Yueqian Deng, William Laframboise, David Bartlett, Russell Schwartz |
Bioinform. | 3 |